symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ACHFF,0.805,1.066851,20342,50392034,0,0.74-2.43,-0.015,Arch Biopartners Inc.,USD,,,,Other OTC,PNK,Biotechnology,https://www.archbiopartners.com,"Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.",Mr. Richard Gabriel Muruve,Healthcare,CA,,,27 Street Clair Avenue East,Toronto,ON,M4T 2M5,,0,https://financialmodelingprep.com/image-stock/ACHFF.png,2002-04-24,True,False,True,False,False
